What happened to the IVD industry? They are all playing acquisitions
Attribute：Industry News Date：2019-09-03 15:49:28
In recent years, with the continuous reform of China's medical system and people's increasing concern for their own health, the demand of in vitro diagnostic reagents market has been driven. With the strong support of national policies, in vitro diagnostic reagents will become an industrial zone with high incidence of mergers and acquisitions in the future.
In vitro diagnostic reagent refers to the reagent for in vitro detection of human samples in the process of disease prevention, diagnosis, treatment monitoring, prognosis observation, health status evaluation and prediction of genetic diseases. Specifically, it is the reagent for detection of various body fluids, cells and tissue samples. It is closely related to people's health, such as detection of pathogens when people go to physical examination In vitro diagnostic reagents are needed to detect antibodies, blood groups, genes and genetic diseases.
1、 Industry status and development trend
China's in vitro diagnostic reagent industry has a certain market scale and foundation, and is stepping into the growth period from the industry introduction period. The market has a good development prospect. From 2007 to 2014, the growth rate of China's IVD market scale was significantly higher than the global average. At present, the monopoly advantage of imported reagents and diagnostic instruments is being broken and restricted by national products. The overall characteristics of China's IVD industry development are large market and greater market potential.
The figure above shows the overall scale of China's in vitro reagent industry from 2007 to 2014, with an average compound growth rate of 16%. The scale of in vitro diagnostic reagents industry in China is relatively small. China's population accounts for more than 1 / 5 of the world's population, but the share of in vitro diagnostic reagents only accounts for 4% of the world's total. The per capita annual consumption of in vitro diagnostic products in China is US $1.50, while that in developed countries is US $25-30.
According to the global IVD reagent market, the largest IVD reagent market is North America, accounting for 44%, while Western Europe accounts for 30%, and Japan and China in Asia account for 11% and 2% respectively.
According to statistical analysis, two thirds of medical decisions depend on diagnostic information, but the income from diagnosis only accounts for 1% of the total medical expenses. It is believed that with the progress of diagnostic technology in the future, it will play a positive role in disease prevention, diagnosis and treatment. Especially for emerging countries, diagnostic reagents are still in a period of rapid development, and the future development space of the industry is very large. At present, the IVD reagent industry as a whole is at the high point of cyclical boom. In the future, China's IVD market will continue to grow by 15% to 20%. Pharmaceutical enterprises are facing good development opportunities. Pharmaceutical enterprises can further expand the market share of IVD reagents by investing in and merging related enterprises.
2、 Competition pattern and market segmentation of global in vitro diagnostic market
In vitro diagnostic reagents include blood, biochemistry, immunity, molecular biology, bacteria, POCT and so on. From the global market of in vitro diagnostic reagents, which is subdivided according to diagnostic methods, immunodiagnosis, clinical biochemical diagnosis and molecular diagnosis occupy the top three. The clinical biochemical diagnosis and immunodiagnosis markets in developed countries are nearly mature, and POCT and molecular diagnosis are the main growth points of the diagnostic market. Immunodiagnostic reagents and clinical biochemical diagnostic reagents are the two major in vitro diagnostic reagent markets in China.
At present, Roche, Abbott, Siemens and Johnson & Johnson are competing in the international in vitro diagnostic reagent market. As Johnson & Johnson divested the clinical diagnostic business of ortho, it ranked fourth in the in vitro diagnostic reagent market.
3、 Frequent mergers and acquisitions of in vitro diagnostic reagents Industry
At present, the market of in vitro diagnostic reagents is good, and pharmaceutical companies are merging and setting foot in the field of in vitro diagnostic reagents. In addition, pharmaceutical companies, which occupy a position in the field of in vitro diagnostic reagents, have also made frequent mergers and acquisitions to expand the product line of diagnostic reagents and increase their market share in in vitro diagnostic reagents. Among them, molecular diagnostic reagents will become a hot spot in the market of in vitro diagnostic reagents.
In April 2014, Roche invested US $450 million to acquire iqum, which focuses on developing instant care products for the molecular diagnosis market. This acquisition enables Roche to quickly enter the immediate diagnosis market segment of molecular diagnosis. At the same time, Roche also obtained the Liat system of iqum company, which can make the nursing staff more close to the patient's nursing site to carry out rapid molecular diagnostic tests with the least training. Roche will further enhance its molecular diagnostics division with cutting-edge technologies and products serving the POC segment.
In July 2014, Illumina acquired myraqa and entered the clinical market. Myraqa focuses on in vitro diagnostics, especially concomitant diagnostics, and focuses on regulatory strategies and application support, including pre marketing approval, pre submission, exemption of test devices, 510 (k), denovo 510 (k) and EU technical documents. The acquisition paves the way for Illumina's application of genomics technology in the regulatory market, including next-generation sequencing, while promoting standards for clinical use.
In September 2014, Beijing Lidman Biochemical Co., Ltd. acquired part of the equity of Desai diagnostic system and Desai diagnostic products. After the completion of the transaction, Lidman will hold 25% and 31% equity of Desai system and Desai products respectively. Desai Diagnostic System Co., Ltd. is a large multinational company, which is headquartered in Frankfurt, Germany, specializing in R & D, production and sales of in vitro diagnostic products. Since 1991, Desai has been the first company in Germany to introduce all liquid, ready-to-use, long-term and stable biochemical diagnostic reagents. It enjoys the reputation of "father of liquid biochemical reagents" in Europe. At the same time, Desai is also the first manufacturer in Europe to obtain CE certification for in vitro diagnostic reagents. The acquisition is a positive expansion of Lidman's market share in biochemical diagnostic reagents.
It has been observed that the market of immunodiagnosis and biochemical diagnosis is close to saturation, and molecular diagnosis will become a hot spot in the market of in vitro diagnostic reagents. Although molecular diagnosis accounts for only 5% at present, it will usher in a high growth period. Molecular diagnosis not only plays an important role in the screening and diagnosis of traditional infectious diseases and genetic diseases, but also is widely used in the fields of individualized diagnosis and treatment of tumor, monitoring of expensive drug treatment, research of drug metabolomics and so on.
Molecular diagnosis is a kind of in vitro detection. The detection object is at the level of genetic material. Molecular biological methods are used to detect the changes of the structure or expression level of genetic material in patients, and then make diagnosis. Compared with other branches of in vitro diagnosis, biochemical diagnosis and immunodiagnosis, they are more specific and precise.
Last：Development status of IVD in China
Next：IVD industry: looking forward to the healthy development under scientific superv...
WhatsApp Online